Showing 5181-5190 of 5771 results for "".
- Aerie Pharmaceuticals Matches ASCRS Foundation Fund Raising to Provide Sight-Saving Surgeryhttps://modernod.com/news/aerie-pharmaceuticals-matches-ascrs-foundation-fund-raising-to-provide-sight-saving-surgery/2476538/Aerie Pharmaceuticals announced that it is matching, dollar for dollar, the first $30,000 donated to the ASCRS Foundation’s charitable eye care programs by attendees at the 2019 ASCRS-ASOA Annual Meeting, being held in San Diego, from May 3-7, 2019. This is the second year that Aerie is d
- Lensar Laser System Receives FDA Clearance to Perform Micro Radial Incisions for Refractive Cataract Procedureshttps://modernod.com/news/lensar-laser-system-receives-fda-clearance-to-perform-micro-radial-incisions-for-refractive-cataract-procedures/2476537/Lensar announced it received 510(k) clearance from the FDA for the Lensar Laser System with Streamline IV, expanding the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post cataract surgery. “This indicat
- Alcon Forms Strategic Alliance to Bring Image-Guided Biometry to the Cataract Refractive Suitehttps://modernod.com/news/alcon-forms-strategic-alliance-to-bring-image-guided-biometry-to-the-cataract-refractive-suite/2476535/Alcon announced a strategic alliance with MOVU to bring an image-guided biometer to global markets. Based in Santa Clara, California, MOVU, a Santec company, is the manufacturer of the ARGOS Swept Source Optical Coherence Tomography (SS-OCT) biometer used to measure eye parameters for patients be
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- New World Medical Recognizes the Recipients of its 2019 Humanitarian Project Award, Health Outcomes Research Award and Fellowship Awardshttps://modernod.com/news/new-world-medical-recognizes-the-recipients-of-its-2019-humanitarian-project-award-health-outcomes-research-award-and-fellowship-awards/2476528/New World Medical has announced the recipients of its annual Humanitarian Project Award, Health Outcomes Research Award, and Fellowship Awards. The Humanitarian Project Award supports a non-profit or academic institution that provides ophthalmic care and skills-transfer. The Health Outcomes Resea
- New President/CEO at The Glaucoma Foundationhttps://modernod.com/news/new-president-ceo-at-the-glaucoma-foundation/2476529/The Board of Directors of The Glaucoma Foundation (TGF) has announced the appointment of Elena Sturman as President and Chief Executive Officer, following the retirement of Scott R. Christensen, who held the position since 2002. She wi
- Avedro Completes Enrollment in Pivotal US Phase 3 Epi-On Corneal Cross-Linking Clinical Trial for Progressive Keratoconushttps://modernod.com/news/avedro-completes-enrollment-in-pivotal-us-phase-3-epi-on-corneal-cross-linking-clinical-trial-for-progressive-keratoconus/2476526/Avedro announced that the company has completed patient enrollment in a pivotal phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (Epi-On) corneal cross-linking procedure for the treatment
- Jim Wachtman Joins CorneaGen as Chief Commercial Officerhttps://modernod.com/news/jim-wachtman-joins-corneagen-as-chief-commercial-officer/2476527/CorneaGen announced that James “Jim” C. Wachtman has joined the young company as chief commercial officer. Mr. Wachtman has been a leader in the cornea community for 20 years and serves as the chair of the Refractive Surgery Council, a group of industry manufacturers and ophthalmologists focused
- Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetingshttps://modernod.com/news/clearside-biomedicals-suprachoroidal-space-injection-platform-featured-at-multiple-ophthalmology-and-gene-therapy-medical-meetings/2476524/Clearside Biomedical announced that multiple presentations were made on Clearside’s Suprachoroidal Space (SCS) injection platform at ophthalmology and gene therapy medical meetings in Vancouver, British Columbia. The presentations highlighted the potential benefits of Clearside’s SCS injection pl
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data